Description: Nyxoah is a pioneering medical device company developing a breakthrough therapeutic solution for the treatment of Obstructive Sleep Apnea (OSA). Nyxoah’s team is driven by the vision that OSA sufferers should benefit from the latest and greatest innovations, for better health outcomes, higher patient comfort and quality of life. At the heart of Nyxoah’s innovation is a unique neurostimulation technology with more than 160 patents submitted worldwide.
Home Page: www.nyxoah.com
NYXH Technical Analysis
Rue Edouard Belin 12
Mont-Saint-Guibert,
1435
Belgium
Phone:
32 1 022 23 55
Officers
| Name | Title |
|---|---|
| Mr. Robert Taub MBA | Co-Founder & Chairman |
| Mr. Olivier Taelman | CEO & Exec. Director |
| Mr. Loic Moreau | Chief Financial Officer |
| Ms. Dorit Nahari | VP of Operations |
| Mr. Bruno Onkelinx | Chief Technology Officer |
| Mr. Jeremy Feffer | VP of Investor Relations & Corp. Communication |
| Ms. An Moonen | Gen. Counsel |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0697 |
| Price-to-Sales TTM: | 73.8386 |
| IPO Date: | 2021-07-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |